Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Bianca Shen

2 papers in the library · publishing 2026

Papers

Effect of Ketamine on Reward Processing in Depressive Disorders: A Systematic Review of Neuroimaging Studies

CNS Spectrums March 10, 2026 Halima Faisal, Gia Han Le, Angela T H Kwan et al.

Ketamine rapidly alters brain reward circuitry in people with major depressive disorder, particularly in fronto-striatal and limbic networks. In a synthesis of 13 neuroimaging studies involving 623 participants (482 with depression, 141 controls), intravenous ketamine (typically 0.5 mg/kg over 40 minutes) changed resting-state connectivity in ventral striatal-prefrontal and default mode, salience, and executive networks within 2 to 48 hours, with some effects lasting up to 10 days. Task-based imaging showed altered ventral striatal responses during reward anticipation and feedback, and changes in medial prefrontal activity during emotion processing. PET scans indicated increased prefrontal-cingulate metabolism and region-specific serotonin receptor binding changes. Few studies directly measured anhedonia, suggesting the findings reflect broader antidepressant mechanisms.

The effect of glutamatergic modulators on sleep behavior and architecture in depressive disorders: A systematic review.

Journal of Psychiatric Research June 1, 2026 Kyle Valentino, Hana Ballum, William Cheung et al.

About 80% of people with major depressive disorder (MDD) report insomnia. This systematic review examined how glutamatergic modulators, especially ketamine, affect sleep in preclinical and clinical studies. Preclinical work showed ketamine alters EEG delta power during NREM sleep and normalizes clock suppressor gene expression, while esketamine enhances delta power but arketamine does not. mGlu2/3 activators reduce REM sleep. Clinical studies indicate that improved sleep can mediate ketamine's antidepressant effects in MDD. The authors suggest that sleep-related mechanisms are potential targets for depression treatment.